MCRB · XBRL financial data
Seres Therapeutics financial statements, every quarter
The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (MCRB's year ends in late December)
| In millions of dollars | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | †Mar 31, 2025 | †Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0* | 0 | 0 | 0 | 0* | 0 | 0 | 0 | 0* | 0 | 1 |
| Revenue from contracts with customers | — | — | — | — | — | — | — | — | 0 | — | — | — |
| Research and development | 28 | 27* | 22 | 18 | 16 | 13* | 12 | 13 | 13 | 12* | 13 | 9 |
| General and administrative | 20 | 17* | 15 | 16 | 13 | 12* | 12 | 10 | 9 | 8* | 8 | 7 |
| Total operating expenses | 48 | 40* | 40 | 31 | 29 | 29* | 27 | 25 | 23 | 20* | 21 | 22 |
| Operating income (loss) | (47) | (40)* | (40) | (31) | (29) | (29)* | (27) | (25) | (22) | (19)* | (21) | (21) |
| Interest income | 3 | 2* | 2 | 1 | 1 | 0* | 1 | 1 | 1 | 0* | 0 | 0 |
| Interest expense | 4 | 4* | 5 | 3 | 0 | 0* | 0 | 0 | — | year only | — | — |
| Other income (expense) | 1 | 0* | 2 | 1 | (23) | 7* | 7 | 4 | 3 | 3* | 1 | 1 |
| Income tax expense (benefit) | 0 | 0* | 0 | 0 | 0 | 0* | 0 | 0 | 0 | 0* | 0 | 0 |
| Net income (loss) | (48) | (41)* | (40) | (33) | 89 | (16)* | 33 | (20) | 8 | (15)* | (20) | 5 |
| Earnings per share, basic‡ USD per share | (7.40) | (6.40)* | (5.40) | (4.40) | 11.60 | (1.80)* | 75.20 | (2.27) | 0.94 | — | (2.08) | 0.47 |
| Earnings per share, diluted‡ USD per share | (7.40) | (6.40)* | (5.40) | (4.40) | 11.60 | (1.80)* | 75.00 | (2.27) | 0.94 | — | (2.08) | 0.47 |
| Weighted average shares, basic‡ millions of shares | 6 | 7* | 7 | 8 | 8 | 9* | 0 | 9 | 9 | — | 10 | 10 |
| Weighted average shares, diluted‡ millions of shares | 6 | 6* | 7 | 8 | 8 | 9* | 0 | 9 | 9 | — | 10 | 10 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (April 2025); filings made before it reported them unadjusted.
- † Share count changed about 1/20 in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 20x in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal quarters (MCRB's year ends in late December)
| In millions of dollars | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | †Mar 31, 2025 | †Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | 170 | 128 | 111 | 71 | 67 | 31 | 59 | 45 | 48 | 46 | 30 | 16 |
| Short-term investments | 0 | 0 | — | — | — | — | — | — | — | — | — | — |
| Accounts receivable | — | — | — | — | — | 0 | — | — | 0 | 0 | 0 | 0 |
| Inventory | 19 | 30 | 42 | 53 | — | — | — | — | — | — | — | — |
| Prepaid and other current assets | 9 | 9 | 5 | 6 | 6 | 6 | 4 | 2 | 3 | 3 | 2 | 1 |
| Total current assets | 214 | 175 | 165 | 149 | 73 | 39 | 66 | 49 | 52 | 49 | 32 | 42 |
| Property and equipment, net | 24 | 22 | 19 | 18 | 13 | 12 | 11 | 10 | 9 | 8 | 7 | 6 |
| Right-of-use asset | 108 | 110 | 106 | 103 | 83 | 81 | 79 | 77 | 75 | 72 | 70 | 51 |
| Total assets | 368 | 359 | 341 | 322 | 179 | 140 | 164 | 144 | 143 | 138 | 118 | 102 |
| Accounts payable | 9 | 4 | 5 | 5 | 8 | 4 | 2 | 2 | 2 | 2 | 2 | 1 |
| Total current liabilities | 79 | 99 | 98 | 108 | 65 | 41 | 31 | 31 | 22 | 19 | 19 | 20 |
| Lease liability, non-current | 105 | 106 | 103 | 101 | 85 | 83 | 80 | 78 | 75 | 73 | 70 | 45 |
| Total liabilities | 383 | 403 | 401 | 409 | 155 | 126 | 114 | 111 | 100 | 94 | 91 | 67 |
| Accumulated deficit | (937) | (978) | (1,018) | (1,051) | (962) | (978) | (945) | (965) | (957) | (972) | (992) | (988) |
| Total stockholders' equity | (15) | (45) | (60) | (87) | 24 | 14 | 50 | 33 | 44 | 44 | 26 | 35 |
| Total liabilities and equity | 368 | 359 | 341 | 322 | 179 | 140 | 164 | 144 | 143 | 138 | 118 | 102 |
| Common shares outstanding (cover page)‡ millions of shares | 6 | 8 | 8 | 8 | 9 | 9 | 0 | 9 | 9 | 10 | 10 | 10 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (April 2025); filings made before it reported them unadjusted.
- † Share count changed about 1/20 in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 20x in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal quarters (MCRB's year ends in late December)
| In millions of dollars | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | †Mar 31, 2025 | †Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (loss) | (48) | (41)* | (40) | (33) | 89 | (16)* | 33 | (20) | 8 | (15)* | (20) | 5 |
| Stock-based compensation | 9* | 5* | 6 | 6* | 5* | 4* | 3 | 2* | 2* | 3* | 2 | 2* |
| Depreciation and amortization | 2 | 2* | 2 | 1 | 1 | 1* | 1 | 1 | 1 | 1* | 1 | 1 |
| Net cash from operating activities | (59)* | (47)* | (35) | (40)* | (35)* | (39)* | 27 | (13)* | 2* | (15)* | (16) | (22)* |
| Purchases of property and equipment | 2* | 1* | 0 | 0* | 0* | 0* | 0 | 0* | 0* | 0* | 0 | 0* |
| Net cash from investing activities | (2)* | (1)* | (0) | 1* | 141* | (0)* | (0) | (0)* | (0)* | 0* | 0 | 0* |
| Proceeds from issuing common stock | — | 0* | — | — | — | year only | — | — | — | — | — | — |
| Net cash from financing activities | 1* | 6* | 19 | 0* | (111)* | 2* | 1 | 0* | 0* | 13* | 0 | 2* |
- † Share count changed about 1/20 in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 20x in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Seres Therapeutics | 16 | 0.7 | (22)* | 9.9M | 0.7 quarters | 10-QJun 30, 2026 |
| Oncolytics Biotech | 4.1 | not reported | (8.1)* | 127.5M | 0.5 quarters | 10-QJun 30, 2026 |
| Gyre Therapeutics | 43 | 29 | (17)* | 111.5M | 3.4 quarters | 10-QJun 30, 2026 |
| Volitionrx | 2.8 | 0.4 | (5.2)* | 13.6M | 0.5 quarters | 10-QJun 30, 2026 |
| Macrogenics | 114 | 33 | (41)* | 63.7M | 2.8 quarters | 10-QJun 30, 2026 |
| Inovio Pharmaceuticals | 32 | 0 | (18)* | 103.4M | 2.0 quarters | 10-QJun 30, 2026 |
| Astria Therapeutics | 96 | 0.7 | (32)* | 57.1M | 7.1 quarters | 10-QSep 30, 2025 |
| Corbus Pharmaceuticals Holdings | 23 | not reported | (30)* | 19.3M | 4.0 quarters | 10-QJun 30, 2026 |
| XBiotech | 110 | not reported | (4.5)* | 30.5M | 24.3 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.